The assignee ranking in this dataset covers 100 companies, with the leading assignee holding 2,759 records against a total of 90,219 in scope. However, concentration is low: the top 5 assignees combined hold only 11.2% of all records, and the top 10 reach just 17.7%. That means the field is defined more by a long tail of moderate and small filers than by a handful of dominant players, so a freedom-to-operate review needs to look well past the leading names.

Filings peaked in 2017 at 826 records and the tracked 2021-2024 window shows a documented 38% decline, from 710 down to 443. Because patent publication typically lags filing by around 18 months, the most recent one to two years in any trend chart are understated by definition, so the apparent drop in 2025-2026 data should not be read as an acceleration. The 2024 figure is the most recent year that can be treated as reasonably complete.

Medicinal preparations (IPC class A61K) is by far the densest category, covering 17.3% of the 90,219 records in scope. Therapeutic activity of compounds (A61P) follows at 6.2%, with peptide and protein chemistry, body-fluid devices, sterilising processes, heterocyclic compounds, implants and microorganism engineering each in the 1.8%-2.8% range. Because a single record can carry multiple classes, these shares add up to more than 100%, but the pattern is clear: formulation chemistry claims are far denser than device or process claims.

Relative to the dense formulation classes, device and process categories such as devices for body fluids, sterilising and disinfecting, implants and prostheses, and microorganism and genetic engineering each sit under 3% of records. Sub-areas named directly in the search scope — continuous biomanufacturing, aseptic processing, inhaled drug delivery devices, and pharmaceutical cold-chain handling — show comparatively less claim density than core small-molecule and antibody formulation work. These are reasonable starting points for a novelty search, though each still needs to be checked against the specific prior art in that branch.

The most-cited records in this corpus include foundational antibody patents such as US8008449B2 (cited 4,535 times) and controlled-release device patents such as US5120548A (cited 3,402 times). High citation counts inside a searched corpus favour older records simply because they have had more time to accumulate citations, so treat these as signals of historical influence and likely prior-art relevance rather than as evidence of current commercial importance. Anyone drafting claims near antibody-conjugate mechanisms or polymer-swelling delivery devices should expect to search against these specific records.